Seagen (SGEN: NASDAQ) Investor Relations Material

Overview

Seattle-based biotechnology company Seagen Inc. is taking the world of cancer treatment by storm with their innovative new therapies. Approaching cancer treatment from all angles, Seagen offers ADCETRIS, an antibody-drug conjugate (ADC) for Hodgkin lymphoma and CD30-positive T-cell lymphomas, as well as PADCEV, an ADC targeting Nectin-4 for advanced or metastatic urothelial cancer. Additionally, Seagen developed TUKYSA, an oral small molecule tyrosine kinase inhibitor, and is working on TIVDAK for metastatic cervical cancer, Ladiratuzumab Vedotin for metastatic breast cancer and solid tumors, Disitamab Vedotin, a novel HER2-targeted ADC, and SEA-TGT and SEA-CD70 for various cancer diseases. With collaborations in place with numerous major players in the industry, including Takeda Pharmaceutical Company Limited, Agensys, Inc., Genmab A/S, Merck, and RemeGen, Co. Ltd, it's clear that Seagen's potential reach is vast. Once known as Seattle Genetics, Inc., the company changed its name to Seagen Inc. in 2020 and has been making waves ever since. Based in Bothell, Washington, Seagen was founded in 1997 and is at the forefront of the fight against cancer.